Newstral
Boehringer Ingelheim
- Zantac didn’t cause 89-year-old woman’s cancer, jury says in first trial over drugNew York Post
- FDA Approves Boehringer Ingelheim’s CYLTEZO® Biosimilar to Humira for Multiple Chronic Inflammatory Diseasesjdsupra.com
- Pfizer agrees to settle over 10K lawsuits linking Zantac to cancerNew York Post
- US challenges ‘bogus’ patents on Ozempic, other drugs to spur competitionreviewjournal.com
- US challenges ‘bogus’ patents on Ozempic and other drugs in effort to spur competitionSeattle Times
- Boehringer Ingelheim Upbeat On China, Forms Cancer Drug PartnershipForbes
- TBiden, Sanders to take victory lap after drugmakers cap cost of inhalersthehill.com
- The Interplay: Key Decisions at the Intersection of Antitrust & Life Sciences - March 2024jdsupra.com
- Could weight-loss drugs eat the world?The Economist
- WAsthma Inhalers Get a Price Cut. Black Users Shouldn’t Breathe Easywordinblack.com
- Experts say Medicaid rebate change is behind inhaler price cutsrollcall.com
- Maryland drug affordability board considers eight drugs for first cost reviewbaltimoresun.com
- A Continuation Application is an Implicit Admission of Obviousness-Type Double Patenting When Filed from a Parent Patentjdsupra.com
- Antitrust Lawsuit Brought Against Drug Manufacturer Based on Its Allegedly Improper Listing of Device Patents in the FDA’s Orange Bookjdsupra.com
- InnovationRx: Peer-Reviewing Health AI ToolsForbes
- Legal Challenges To IRA Drug Price Negotiations Face Skeptical JudgesForbes
- The battle over the trillion-dollar weight-loss bonanzaThe Economist
- Healthtech secures $4.2m Pre-Series A fundingtribuneonlineng.com
- Year in Review: Top Legal Developments of 2023jdsupra.com
- Washington Healthcare Update - January 2024jdsupra.com
Frequent names
Newstral's extraction of names of people and organisations from the world's news is completely automated. If you do not want your name to appear here, please contact us. We will be happy to look at your request.